The metabolic disposition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the induced mouse

Ken W Turteltaub, M. G. Knize, S. K. Healy, J. D. Tucker, J. S. Felton

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The toxicokinetics of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a member of the aminoimidazoazaarene family of mutagens, was studied in C57BL/6 male mice after ip and gavage exposure to a single dose of 100 mg/kg body weight. Twenty-four hr after administration of the dose, 39% of the [14C]PhIP had been found in the urine of the animals exposed ip and 12% had been found in the faeces. By comparison, at 24 hr, gavage-exposed animals had excreted 31% of the administered radioactivity in the urine and 30% in the faeces. Significantly higher levels of labelled compounds could be detected in the blood of animals dosed ip than in that of those dosed by gavage at 6 and 12 hr after dosing. Tissue concentrations of labelled compound were highest in the liver and gastro-intestinal tract of the ip group and the large intestine of the gavage group. Considerable radioactivity was also detected in the contents of the large and small intestine of the ip group suggesting biliary excretion of PhIP. Peak tissue concentrations were found 6-12 hr after administration of the dose by both routes. High-performance liquid chromatography of urine demonstrated the presence of 11 metabolites while only two major metabolites were found in the faeces, one of which was not present in the urine. None of the metabolites appeared to be formed by simple N-acetylations or N-demethylations of PhIP. No differences were seen in the metabolite profiles between the ip and the gavage groups, but significant differences were seen in the kinetics of PhIP excretion between animals dosed by these two routes. These data indicate that the toxicokinetics of PhIP metabolism differ depending on the route of administration and should be considered when performing animal studies to assess the significance of human dietary PhIP consumption.

Original languageEnglish (US)
Pages (from-to)667-673
Number of pages7
JournalFood and Chemical Toxicology
Volume27
Issue number10
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

pyridines
urine
mice
metabolites
Metabolites
Animals
feces
large intestine
animals
pharmacokinetics
Feces
Urine
excretion
dosage
Large Intestine
Radioactivity
acetylation
gastrointestinal system
small intestine
Tissue

ASJC Scopus subject areas

  • Food Science
  • Toxicology

Cite this

The metabolic disposition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the induced mouse. / Turteltaub, Ken W; Knize, M. G.; Healy, S. K.; Tucker, J. D.; Felton, J. S.

In: Food and Chemical Toxicology, Vol. 27, No. 10, 1989, p. 667-673.

Research output: Contribution to journalArticle

Turteltaub, Ken W ; Knize, M. G. ; Healy, S. K. ; Tucker, J. D. ; Felton, J. S. / The metabolic disposition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the induced mouse. In: Food and Chemical Toxicology. 1989 ; Vol. 27, No. 10. pp. 667-673.
@article{7c2245973f734521bbc540586c1268ce,
title = "The metabolic disposition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the induced mouse",
abstract = "The toxicokinetics of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a member of the aminoimidazoazaarene family of mutagens, was studied in C57BL/6 male mice after ip and gavage exposure to a single dose of 100 mg/kg body weight. Twenty-four hr after administration of the dose, 39{\%} of the [14C]PhIP had been found in the urine of the animals exposed ip and 12{\%} had been found in the faeces. By comparison, at 24 hr, gavage-exposed animals had excreted 31{\%} of the administered radioactivity in the urine and 30{\%} in the faeces. Significantly higher levels of labelled compounds could be detected in the blood of animals dosed ip than in that of those dosed by gavage at 6 and 12 hr after dosing. Tissue concentrations of labelled compound were highest in the liver and gastro-intestinal tract of the ip group and the large intestine of the gavage group. Considerable radioactivity was also detected in the contents of the large and small intestine of the ip group suggesting biliary excretion of PhIP. Peak tissue concentrations were found 6-12 hr after administration of the dose by both routes. High-performance liquid chromatography of urine demonstrated the presence of 11 metabolites while only two major metabolites were found in the faeces, one of which was not present in the urine. None of the metabolites appeared to be formed by simple N-acetylations or N-demethylations of PhIP. No differences were seen in the metabolite profiles between the ip and the gavage groups, but significant differences were seen in the kinetics of PhIP excretion between animals dosed by these two routes. These data indicate that the toxicokinetics of PhIP metabolism differ depending on the route of administration and should be considered when performing animal studies to assess the significance of human dietary PhIP consumption.",
author = "Turteltaub, {Ken W} and Knize, {M. G.} and Healy, {S. K.} and Tucker, {J. D.} and Felton, {J. S.}",
year = "1989",
doi = "10.1016/0278-6915(89)90121-X",
language = "English (US)",
volume = "27",
pages = "667--673",
journal = "Food and Chemical Toxicology",
issn = "0278-6915",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - The metabolic disposition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the induced mouse

AU - Turteltaub, Ken W

AU - Knize, M. G.

AU - Healy, S. K.

AU - Tucker, J. D.

AU - Felton, J. S.

PY - 1989

Y1 - 1989

N2 - The toxicokinetics of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a member of the aminoimidazoazaarene family of mutagens, was studied in C57BL/6 male mice after ip and gavage exposure to a single dose of 100 mg/kg body weight. Twenty-four hr after administration of the dose, 39% of the [14C]PhIP had been found in the urine of the animals exposed ip and 12% had been found in the faeces. By comparison, at 24 hr, gavage-exposed animals had excreted 31% of the administered radioactivity in the urine and 30% in the faeces. Significantly higher levels of labelled compounds could be detected in the blood of animals dosed ip than in that of those dosed by gavage at 6 and 12 hr after dosing. Tissue concentrations of labelled compound were highest in the liver and gastro-intestinal tract of the ip group and the large intestine of the gavage group. Considerable radioactivity was also detected in the contents of the large and small intestine of the ip group suggesting biliary excretion of PhIP. Peak tissue concentrations were found 6-12 hr after administration of the dose by both routes. High-performance liquid chromatography of urine demonstrated the presence of 11 metabolites while only two major metabolites were found in the faeces, one of which was not present in the urine. None of the metabolites appeared to be formed by simple N-acetylations or N-demethylations of PhIP. No differences were seen in the metabolite profiles between the ip and the gavage groups, but significant differences were seen in the kinetics of PhIP excretion between animals dosed by these two routes. These data indicate that the toxicokinetics of PhIP metabolism differ depending on the route of administration and should be considered when performing animal studies to assess the significance of human dietary PhIP consumption.

AB - The toxicokinetics of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a member of the aminoimidazoazaarene family of mutagens, was studied in C57BL/6 male mice after ip and gavage exposure to a single dose of 100 mg/kg body weight. Twenty-four hr after administration of the dose, 39% of the [14C]PhIP had been found in the urine of the animals exposed ip and 12% had been found in the faeces. By comparison, at 24 hr, gavage-exposed animals had excreted 31% of the administered radioactivity in the urine and 30% in the faeces. Significantly higher levels of labelled compounds could be detected in the blood of animals dosed ip than in that of those dosed by gavage at 6 and 12 hr after dosing. Tissue concentrations of labelled compound were highest in the liver and gastro-intestinal tract of the ip group and the large intestine of the gavage group. Considerable radioactivity was also detected in the contents of the large and small intestine of the ip group suggesting biliary excretion of PhIP. Peak tissue concentrations were found 6-12 hr after administration of the dose by both routes. High-performance liquid chromatography of urine demonstrated the presence of 11 metabolites while only two major metabolites were found in the faeces, one of which was not present in the urine. None of the metabolites appeared to be formed by simple N-acetylations or N-demethylations of PhIP. No differences were seen in the metabolite profiles between the ip and the gavage groups, but significant differences were seen in the kinetics of PhIP excretion between animals dosed by these two routes. These data indicate that the toxicokinetics of PhIP metabolism differ depending on the route of administration and should be considered when performing animal studies to assess the significance of human dietary PhIP consumption.

UR - http://www.scopus.com/inward/record.url?scp=0024833679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024833679&partnerID=8YFLogxK

U2 - 10.1016/0278-6915(89)90121-X

DO - 10.1016/0278-6915(89)90121-X

M3 - Article

VL - 27

SP - 667

EP - 673

JO - Food and Chemical Toxicology

JF - Food and Chemical Toxicology

SN - 0278-6915

IS - 10

ER -